ClinicalTrials.Veeva

Menu
K

Klinikum Chemnitz gGmbH | Oncological Center Chemnitz

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Carboplatin
Azacitidine
Lenalidomide
Atezolizumab
Dexamethasone
Bevacizumab
Gemcitabine
cyclophosphamide
Daratumumab
ifosfamide

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

36 of 104 total trials

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte)

Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab...

Active, not recruiting
Small-Cell Lung Cancer
Drug: Atezolizumab
Drug: Lurbinectedin

The Alternative-C Trial is a prospective, multicenter Phase 2 Study to evaluate the efficacy of the chemotherapy-free combination of copanlisib and o...

Active, not recruiting
Follicular Lymphoma
Drug: Obinutuzumab
Drug: Copanlisib

This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Carboplatin
Drug: Cisplatin

A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Pomalidomide

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with elig...

Enrolling
Non-Small Cell Lung Cancer
Drug: Durvalumab
Drug: Entrectinib

The purpose of this study is to identify the recommended Phase 2 combination dose (RP2CD\[s\]) of the amivantamab and capmatinib combination therapy...

Enrolling
Carcinoma, Non-Small-Cell Lung
Drug: Amivantamab
Drug: Capmatinib

The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma bene...

Enrolling
Multiple Myeloma
Drug: Carfilzomib
Drug: Daratumumab

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Venetoclax
Drug: Azacitidine

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed a...

Active, not recruiting
Non-small Cell Lung Cancer (NSCLC)
Drug: Tiragolumab Matching Placebo
Drug: Carboplatin

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk...

Active, not recruiting
HER2-Positive Primary Breast Cancer
Residual Invasive Breast Cancer
Drug: DS-8201a
Drug: T-DM1

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling
PBC
Primary Biliary Cholangitis
Drug: Placebo
Drug: Volixibat

This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immuno...

Enrolling
Non-Small Cell Lung Cancer
Drug: Docetaxel
Drug: Entrectinib

This study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older....

Active, not recruiting
Idiopathic Pulmonary Fibrosis
Drug: Placebo
Drug: BI 1015550

This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic...

Active, not recruiting
Lung Diseases, Interstitial
Drug: BI 1015550
Drug: Placebo

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Rituximab

This phase I/II clinical trial evaluates the safety and efficacy of the combined administration of midostaurin and gemtuzumab ozogamicin in the frame...

Enrolling
Acute Myeloid Leukemia
Drug: MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin
Drug: MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO

Brief Summary:The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFie...

Active, not recruiting
Pancreas Adenocarcinoma
Drug: Gemcitabine
Drug: nab paclitaxel

Adult male and female patients with newly diagnosed Philadelphia chromosome positive (Ph+) and/or BCR-ABL1 positive CML can be included in the study...

Active, not recruiting
Chronic Myeloid Leukemia
Drug: Nilotinib 300 mg
Drug: Dasatinib

To assess the safety and efficacy of galinpepimut-S (GPS) compared with investigator's choice of best available therapy (BAT) on overall survival (OS...

Active, not recruiting
Acute Myeloid Leukemia
Biological: Galinpepimut-S
Drug: Azacitidine

Trial sponsors

Roche logo
Pfizer logo
AbbVie logo
Boehringer Ingelheim logo
Janssen (J&J Innovative Medicine) logo
T
G
G
U
Amgen logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems